

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313 on April 21, 2004

By: 

PATENT

Attorney Docket No.: 02558P-001340US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

James Blake *et al.*

Application No.: 09/733,239

Filed: December 8, 2000

For: CYSTEINE THIOL-PROTECTED
PEPTIDES FOR USE IN
IMMUNOASSAYS

Examiner: Unassigned

Art Unit: 1648

**RESPONSE TO RESTRICTION
REQUIREMENT and SEQUENCE
DISCLOSURE REQUIREMENTS**

Assistant Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Restriction Requirement dated February 23, 2004, which set forth the following groups of claims:

- I. Claims 1-13, drawn to the peptide identified in claim 9, classified in class 530, subclass 300.
- II. Claims 1-8, 14-18, drawn to the peptide identified in claim 14, classified in class 530, subclass 300.
- III. Claims 1-8, 19-23, drawn to the peptide identified in claim 19, classified in class 530, subclass 300.
- IV. Claims 1-8, 24-28, drawn to the peptide identified in claim 24, classified in class 530, subclass 300.

Applicants elect to prosecute Group I, claims 1-13, with traverse. Applicants reserve the right to file a divisional or related application to any claim of a non-elected group.

Further, in response to the Examiner's request to provide a sequence listing, Applicants submit the enclosed paper copy of the sequence listing to be made of record in the above-referenced application and a computer readable form (CRF) copy of the Sequence Listing. Pursuant to 37 CFR §1.821(f) and (g), it is believed that the content of the paper sequence listing and the computer readable sequence listing are the same. Further, the present submission of the Paper Sequence Listing and CRF Sequence Listing is not believed to constitute new matter.

In addition, pursuant to 37 CFR §1.125, Applicants submit herewith a substitute specification (clean copy and marked up copy) to show the Sequence Identifiers.

Applicants believe all requirements for responding to the restriction requirement have been addressed. If a telephone conference would expedite this matter, the Examiner is respectfully encouraged to contact the undersigned accordingly.

Respectfully submitted,

Dated: 21 April 2004

By: Brian W. Poor
Brian W. Poor
Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, CA 94111
(206) 467-9600
60161457 v1